The Analytical Blueprint for Cell & Gene Therapy Success

Read Now

Cell and gene therapies have entered a new phase of maturity. Scientific innovation continues at an unprecedented pace, but so do the analytical and regulatory expectations that determine whether promising therapies ultimately reach patients.

Throughout 2026, the regulatory landscape has continued to evolve. The FDA introduced new CMC flexibilities designed specifically for cell and gene therapies, recognizing that traditional development paradigms do not always fit these complex products. At the same time, newly published Complete Response Letters have continued to provide valuable insight into the analytical deficiencies that most frequently delay approvals, while upcoming new ICH guidance and USP chapters are further shaping expectations for extractables and leachables.

Taken together, these developments highlight the growing importance of analytical science. Analytics has become a strategic discipline that supports product understanding, guides manufacturing decisions, informs risk assessments, and builds confidence throughout the product lifecycle. Developers must establish an integrated analytical strategy that evolves alongside the product, connecting characterization, potency, safety, manufacturing, and regulatory requirements into a comprehensive understanding of quality.

This eBook brings together expert perspectives on several of the most pressing analytical topics facing today’s cell and gene therapy developers. Inside, you’ll explore how integrated analytics can help prevent program drift, how next-generation sequencing is transforming product characterization and viral safety, why extractables and leachables require new approaches for CGTs, what FDA Complete Response Letters reveal about potency assays, and how recent FDA CMC flexibilities can be leveraged to accelerate development. You’ll also see how complementary genomic technologies can be combined to solve complex characterization challenges through a real-world case study.

Although each article addresses a different aspect of development, they all reinforce the same message: thoughtful analytical strategies reduce uncertainty, strengthen regulatory readiness, and ultimately help move innovative therapies from the laboratory to the patients who need them most.

The post The Analytical Blueprint for Cell & Gene Therapy Success appeared first on GEN - Genetic Engineering and Biotechnology News.